Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-1236. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 known ✓ | P39900 | 5/20 | 0.74 |
| ▸ | MMP13 | P45452 | 20/20 | 0.74 |
| ▸ | MMP14 | P50281 | 10/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1236 SCHEMBL940419 | 1.00 | MMP13 (0.74) | MMP13MMP12MMP14 | |
| Azd-1236 SCHEMBL942315 | 1.00 | MMP13 (0.74) | MMP13MMP12MMP14 | |
| Azd-1236 SCHEMBL29464251 | 1.00 | MMP13 (0.74) | MMP13MMP12MMP14 | |
| SCHEMBL942517 | 0.89 | MMP13 (0.65) | MMP13MMP12MMP14 | |
| SCHEMBL4783467 | 0.89 | MMP13 (0.65) | MMP13MMP12MMP14 | |
| SCHEMBL941741 | 0.89 | MMP13 (0.64) | MMP13MMP12MMP14 | |
| SCHEMBL941847 | 0.89 | MMP13 (0.64) | MMP13MMP12MMP14 | |
| SCHEMBL4782766 | 0.89 | MMP13 (0.64) | MMP13MMP12MMP14 | |
| SCHEMBL941752 | 0.88 | MMP13 (0.70) | MMP13MMP12MMP14 | |
| SCHEMBL4558815 | 0.87 | MMP13 (0.55) | MMP13MMP12MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2007106022-A2 | A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221640-A1 | Novel Crystal Modifications | PTMS, NT5C, CDK5 | MMP12 4358/4885MMP13 4294/4885MMP14 4245/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MMP12 1/4885MMP13 19/4885MMP14 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.